• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Culmination Bio Raises $10M to Bring Longitudinal Health Data to Biopharma

Share:

December 4, 2023

Culmination Bio secures a $10 million investment from Merck GHI and Amgen Ventures for its disease-agnostic patient data intelligence platform, stemming from a spinoff from Intermountain Health. Their extensive data lake spans 40+ years of de-identified patient records and biospecimens, aiding biopharmaceutical advancements. The funding facilitates platform enhancement, offering biotech firms access to millions of patient samples and accelerating research with streamlined data access, potentially expediting critical discoveries in healthcare.

What You Should Know:

Culmination Bio, a company building the largest disease-agnostic patient data intelligence platform, today announced a $10 million investment from Merck Global Health Innovation Fund (Merck GHI) and Amgen Ventures.
As a spinoff from Intermountain Health, Culmination Bio maintains exclusive rights to a physical library and cloud-based data lake covering over 40 years of de-identified patient electronic health records and biospecimen data.
Data Driven Insights Enabled by Merck and Amgen Fundings

As the most extensive repository of its kind, this data lake empowers biopharmaceutical companies by providing crucial insights necessary for advancing diagnostic and therapeutic development. The recent funding secured by Culmination Bio will enable the further enhancement of its exclusive Intelligence Platform and the expansion of its commercial growth.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Presently, there is no streamlined method for bringing a drug or diagnostic to market, with the process often extending over a decade and incurring billions of dollars in costs for regulatory approval. The challenge originates from the time-consuming task of acquiring longitudinal biological and clinical patient data, a process that takes life sciences and biotech companies months to complete.

Culmination Bio addresses this hurdle by offering a continually expanding library of over five million de-identified patient samples and clinical data spanning several decades. Biotech and life sciences companies collaborate with Culmination Bio to swiftly access retrospective patient data and efficiently reach thousands of prospective patients for their studies.

“With support from our investors, Culmination Bio is raising the bar for healthcare innovation,” said Lincoln Nadauld, MD, Ph.D., president and CEO of Culmination Bio. “On top of our existing longitudinal patient data, we are adding over 300,000 biospecimens to our data lake each year. Because of this, we have the ability to quickly identify unique patient cohorts from our vast data lake that can speed up critical research, leading to novel discoveries..”

Source: Hit Consultant

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Bridge Connector Lands $25.5M to Expand Healthcare Integration PlatformBridge Connector Lands $25.5M to Expand Healthcare Integration Platform
  • Health Tech Giant Philips Launches New Digital Pathology PlatformHealth Tech Giant Philips Launches New Digital Pathology Platform
  • An end to rebates as we know them? HHS plan would punch PBMs, but pharma might benefitAn end to rebates as we know them? HHS plan would punch PBMs, but pharma might benefit
  • GYANT Develops First-to-Market COVID-19 Vaccine Care Navigation ToolGYANT Develops First-to-Market COVID-19 Vaccine Care Navigation Tool
  • Philips-Medisize launches third-gen Connected Health PlatformPhilips-Medisize launches third-gen Connected Health Platform
  • Inizio Acquires Evolution Road, Bolstering Evoke’s Digital Innovation and Omnichannel OfferingInizio Acquires Evolution Road, Bolstering Evoke’s Digital Innovation and Omnichannel Offering
  • Hospital Wayfinding: The Next Frontier in Healthcare DesignHospital Wayfinding: The Next Frontier in Healthcare Design
  • Octave Bags $11m Series A for In-person, Virtual Behavioral CareOctave Bags $11m Series A for In-person, Virtual Behavioral Care

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications